XML 41 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Revenue from Contracts with Customers (Tables)
3 Months Ended
Mar. 31, 2025
Revenue from Contracts with Customers  
Schedule of product revenue provision and allowance categories

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2024

$

191,508

$

147,134

$

38,512

Provision related to current period sales

119,726

17,212

50,169

Ironshore measurement period adjustments

638

(14,765)

Changes in estimate related to prior period sales

1,675

(1,782)

303

Credits/payments made

(125,261)

(11,420)

(60,861)

Balance as of March 31, 2025

$

188,286

$

136,379

$

28,123

    

    

Trade

Rebates and

Product

Allowances and

Incentives (1)

Returns (2)

Chargebacks (3)

Balance as of December 31, 2023

$

149,826

$

77,505

$

20,917

Provision related to current period sales

92,569

9,697

39,013

Changes in estimate related to prior period sales

1,061

1,519

(53)

Credits/payments made

(105,228)

(9,069)

(39,245)

Balance as of March 31, 2024

$

138,228

$

79,652

$

20,632

(1)Provisions for rebates and incentives include managed care rebates, government rebates and co-pay program incentives. Provisions for rebates and incentives are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(2)Provisions for product returns are deducted from gross revenues at the time revenues are recognized and are included in accrued rebates, returns and discounts in the Company’s Condensed Consolidated Balance Sheets.
(3)Provisions for trade allowances and chargebacks include fees for distribution service fees, prompt pay discounts, and chargebacks. Trade allowances and chargebacks are deducted from gross revenue at the time revenues are recognized and are recorded as a reduction to accounts receivable in the Company’s Condensed Consolidated Balance Sheets.
Schedule of disaggregation of revenue

Three Months Ended March 31,

2025

2024

Belbuca

$

51,658

$

50,663

Xtampza ER

47,642

    

45,813

Jornay PM

28,539

Nucynta IR

27,417

25,960

Nucynta ER

19,686

19,186

Symproic

2,815

3,301

Total product revenues, net

$

177,757

$

144,923